Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Shares Outstanding (Diluted Average): 2019-2025

Historic Shares Outstanding (Diluted Average) for Ultragenyx Pharmaceutical (RARE) over the last 4 years, with Sep 2025 value amounting to $99.8 million.

  • Ultragenyx Pharmaceutical's Shares Outstanding (Diluted Average) rose 4.48% to $99.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $99.8 million, marking a year-over-year increase of 4.48%. This contributed to the annual value of $90.5 million for FY2024, which is 23.11% up from last year.
  • Per Ultragenyx Pharmaceutical's latest filing, its Shares Outstanding (Diluted Average) stood at $99.8 million for Q3 2025, which was up 1.33% from $98.5 million recorded in Q2 2025.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Shares Outstanding (Diluted Average) peaked at $99.8 million during Q3 2025, and registered a low of $67.8 million during Q4 2021.
  • In the last 3 years, Ultragenyx Pharmaceutical's Shares Outstanding (Diluted Average) had a median value of $86.6 million in 2024 and averaged $85.3 million.
  • Data for Ultragenyx Pharmaceutical's Shares Outstanding (Diluted Average) shows a peak YoY spiked of 33.25% (in 2024) over the last 5 years.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Shares Outstanding (Diluted Average) (Quarterly) stood at $67.8 million in 2021, then grew by 3.13% to $69.9 million in 2022, then increased by 5.19% to $73.5 million in 2023, then rose by 23.11% to $90.5 million in 2024, then rose by 4.48% to $99.8 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $99.8 million in Q3 2025, compared to $98.5 million in Q2 2025 and $96.3 million in Q1 2025.